Health Care · Pharmaceuticals
Merck & Company, Inc. MRK
$127.49-0.14 (-0.11%)delayed quote · as of 2026-07-17 19:18 UTC
Market cap
$314.9B
Previous close
$127.63
Volume
9.3M
52-week range
$76.66 – $131.74
Verdictconfidence 96% · high
Growth, Health and Momentum stand out; quality flashes caution.
4 of 5 dimensions score well; quality flashes caution.
Value603/5 checks
Growth804/5 checks
Quality251/4 checks
Health804/5 checks
Momentum1005/5 checks
Fair-value estimate $315.48 per share (2-stage FCF · individual beta · 10Y Rf 4.5%) — the price sits 60% below it.
Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.
Key ratioslatest filing FY 2025
Value
P/E TTM
36.0
P/E NTM
13.2
EV/EBITDA
12.2
PEG
6.11
FCF yield
3.9%
Growth
Revenue 3y
+3.1%/yr
Revenue YoY
+1.3%
Expected EPS
+171.6%
Quality
Piotroski F
5 / 9
ROIC
ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-17 19:18 UTC · fundamentals FY 2025 · SEC EDGAR
Continue with MRK in ALAN
Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.
For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.